Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of mouse embryonic fibroblast-TBX2 cells treated with LPA or EGF
EXPERIMENT 3: LPA compared to EGF response; LPA concentration 5uM; EGF concentration 50ng/ml
ORGANISM(S): Mus musculus 
2009-02-14 | E-NCMF-18 | biostudies-arrayexpress
UnknownMultiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling.
Not available
S-EPMC2536681 | biostudies-literature
UnknownPost-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection.
Not available
S-EPMC4970669 | biostudies-literature
TranscriptomicsTranscription profiling of mouse embryonic fibroblast-TBX2 cells treated with LPA or EGF and their inhibitors
EXPERIMENT 4: Effect of inhibitors on 4 hrs LPA response Concentration LPA 5 uM Concentration AG1478/PD168393 250 nM Concentration PTX 200 ng/ml
ORGANISM(S): Mus musculus 
2009-02-14 | E-NCMF-19 | biostudies-arrayexpress
UnknownNon-linear antigenic regions in epidermal growth factor (EGF) and transforming growth factor alpha (TGF alpha) studied by EGF-TGF alpha chimaeras.
Not available
S-EPMC1221147 | biostudies-literature
UnknownDelivery of an anti-transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons.
Not available
S-EPMC6001800 | biostudies-literature
TranscriptomicsTranscription profiling of time series of mouse embryonic fibroblast-TBX2 cells treated with LPA
EXPERIMENT 1: LPA effect time series LPA concentration 5uM timepoints 0, 0.5, 1, 2, 4, 6 and 24 hrs
ORGANISM(S): Mus musculus 
2009-02-14 | E-NCMF-16 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of time series of mouse embryonic fibroblast-TBX2 cells treated with LPA at different concentrations
EXPERIMENT 2: LPA concentration and time series LPA concentration 0.3, 1.0 and 5.0 uM Time series 0.5, 1, 2 and 4 hrs
ORGANISM(S): Mus musculus 
2009-02-14 | E-NCMF-17 | biostudies-arrayexpress
UnknownGeneration and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
Not available
S-EPMC4704182 | biostudies-literature
UnknownEffective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs.
Not available
S-EPMC9589454 | biostudies-literature
Sort   by:  
 Page size